About Auro Peptides Limited
Data last updated: 22 December 2025
Auro Peptides Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Aurobindo Pharma Ltd. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 02 January 2012, the company has been in operation for over 14 years.
Registered with ROC Hyderabad under CIN U24232AP2012PLC078350.
Capital: an authorised share capital of ₹450.1 Cr and a paid-up capital of ₹336.1 Cr. It is led by directors including Sivakumaran Meenakshisunderam and Mudiraj Saritha Rani.
Last AGM: 01 September 2025. Financial statements filed for year ended 31 March 2025. Office: Galaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032.
As per the financials filed for FY 2025, the company reported a revenue of ₹23.52 Cr, a decline of 14% compared to the previous year.
The company has a workforce of approximately 169 employees as per the latest available data. It operates as a subsidiary of Aurobindo Pharma Ltd.
The company is associated with 1 brand - Aurobindo Pharma.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aurobindo.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressGalaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Auro Peptides Limited
Auro Peptides Limited has one previous CIN (Corporate Identification Number): U24232AP2012PLC078350. The current CIN is U24232TG2012PLC078350, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2012PLC078350 | Current |
| U24232AP2012PLC078350 | Previous |
Associated Brands with Auro Peptides Limited
Auro Peptides Limited operates one associated brand: Aurobindo Pharma. These brands represent Auro Peptides Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Generic biocatalytic solutions are provided for pharmaceutical applications. | aurobindo.com |
Competitors & Alternatives of Auro Peptides Limited
Brands and companies operating in the same space as Auro Peptides Limited include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Seqens
|
Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
Asymchem
|
APIs and peptides are developed and manufactured by Asymchem. | Morrisville, United States, United States | 1995 |
Biophore
|
Niche generic pharmaceuticals are developed and manufactured for industry needs. | Hyderabad, India, India | 2007 |
Continuus Pharma
|
MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | Woburn, United States, United States | 2012 |
Business Activity of Auro Peptides Limited
Auro Peptides Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Board of Directors of Auro Peptides Limited
Auro Peptides Limited is currently managed by 8 directors, with 16 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Sivakumaran Meenakshisunderam
Also directs:
Curateq Biologics Private Limited, Tergene Biotech Limited, Apl Healthcare Limited and 2 more
|
Director | 29 Sep 2017 | 8 Years 9 Months | Current |
| Mudiraj Saritha Rani | Director | 15 Jun 2022 | 4 Years 0 Months | Current |
| Chandra Reddy Tirumalareddy | Whole-Time Director | 23 May 2019 | 7 Years 1 Months | Current |
|
Mylandlahalli Rammohan Ashwini
Also directs:
Curateq Biologics Private Limited, Apl Healthcare Limited, Auro Vaccines Private Limited and 3 more
|
Additional Director | 30 Oct 2025 | 0 Years 8 Months | Current |
|
Satakarni Makkapati
Also directs:
Aurobindo Pharma Ltd, Engenra Biologics Private Limited, Theranym Biologics Private Limited and 2 more
|
Director | 02 Nov 2021 | 4 Years 8 Months | Current |
| Naga Venkata Subbarao Kesavarapu | Director | 20 Jan 2023 | 3 Years 5 Months | Current |
Financials of Auro Peptides Limited FY 2025 filings available
Auro Peptides Limited reported revenue of ₹23.52 Cr (down 14% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings Auro Peptides Limited
Auro Peptides Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Auro Peptides Limited
View historical data on people associated with Auro Peptides Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Auro Peptides Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Auro Peptides Limited
GSTIN & GST Filing Data of Auro Peptides Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Auro Peptides Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Auro Peptides Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Auro Peptides Limited
MSME Payment Delays by Auro Peptides Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Auro Peptides Limited
Subsidiaries & Group Companies of Auro Peptides Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Auro Peptides Limited with ownership details.
MCA Filings & Documents of Auro Peptides Limited
MCA Filings & Documents of Auro Peptides Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Auro Peptides Limited
Recent News on Auro Peptides Limited
Frequently Asked Questions about Auro Peptides Limited
Auro Peptides Limited is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 02 January 2012 (14+ years old) and is registered under CIN U24232TG2012PLC078350. The company has 169 employees.
Auro Peptides Limited reported revenue of ₹23.52 Cr for FY 2025 (down 14.00% YoY).
The current directors of Auro Peptides Limited are:
The primary industry of Auro Peptides Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Auro Peptides Limited can be reached at the registered office: Galaxy Floors 22 – 24 Plot No. 1 Survey No. 831 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032, or through the website aurobindo.com.
The authorised capital is ₹450.1 Cr, and the paid-up capital is ₹336.1 Cr.